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ABSTRACT 
Objective: The present study was carried out to evaluate the adverse effects of cefotaxime at two different doses on some biochemical parameters 
in albino rats. Histopathological changes in liver and kidney induced by cefotaxime were also investigated.  
Methods: Thirty rats were randomly divided into 3 equal groups; the first group was received distilled water and kept as a control. The second 
group was received cefotaxime (90 mg/kg b. wt), while the third group was received cefotaxime (180 mg/kg b. wt). Cefotaxime at different doses 
were injected intramuscularly (IM) twice daily at 12 h intervals for 7 consecutive days.  
Results: The obtained results showed that, cefotaxime produced significant elevation in creatinine, urea, sodium, potassium, calcium concentrations 
and decrease concentrations of both glucose and total protein in the serum of treated rats. Also, cefotaxime caused an elevation in some biochemical 
parameters as (Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), total bilirubin, Cholesterol, Triglycerides and Low density 
lipoprotein-cholesterol (LDL-chol) and decrease in albumin, High density lipoprotein-cholesterol (HDL-chol) concentrations in serum of treated 
rats. Histopathological alterations were observed in liver and kidney.  
Conclusions: It could be concluded that administration of cefotaxime induced some adverse effects on biochemical parameters as well as 
histopathological changes in liver and kidney.  
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INTRODUCTION 
Cefotaxime is a third-generation cephalosporin antibacterial drug 
commonly used to treat upper respiratory tract infections and 
bacterial meningitis. Approximately 40%-60% of cefotaxime is 
excreted unchanged in the urine [1, 2]. Cefotaxime has an excellent 
bactericidal activity against a wide variety of Gram-negative and 
most of the Gram-positive micro-organisms, particularly β-
lactamase producing strains [3].  
It has a very important place in antimicrobial therapy because of its 
relatively expanded spectrum of antimicrobial activity, greater 
resistance to β-lactamase [4]. Cefotaxime belongs to class 3 of the 
Biopharmaceutics Drug Disposition Classification System (BDDCS), 
which are characterized by high water solubility, poor passive 
permeability, and poor metabolism [5]. 
Liver plays a central role in metabolism of drug and xenobiotics, 
protein synthesis and in maintaining biologic equilibrium, of 
organisms. Due to these important roles, liver enzymes are used as 
markers in the assessment of drug safety or toxicity [6]. The 
transaminases are involved in intermediary metabolism and are 
thus present in high concentration in the liver; they are rapidly 
released into the serum in cases of acute destruction of tissues as in 
myocardial infarction or hepatocellular necrosis [7]. 
Kidney is an important organ having not only excretory function but 
also other functions such as production of the substances that 
activates a living body, enzymatic reaction, immunization. The 
kidney is often involved in the development, maintenance and 
counter regulation of complex electrolyte disturbances [8]. 
Since antibiotics are used for treatment of infections that may cause 
changes in some biochemical parameters, the physician or 
veterinarian must take in consideration the changes caused by these 
drugs to avoid incorrect diagnosis. I hypothesized that chronic 
administration of cefotaxime in high doses may severely damage the 
liver and kidneys with significant alterations in the parameters. The 
main purpose of this study is to investigate and provide an overview 
of the biochemical changes in serum of treated rats and 
histopathological changes of the liver and kidney following 
intramuscular administration of cefotaxime as its misuse or over 
dosage administration may cause a lot of adverse effects in human 
and veterinary medicine.  
MATERIALS AND METHODS 
Drug 
Cefotaxime is used for IM or IV injection in strengths equivalent to 
250 mg, 500 mg and 1gof cefotaxime sodium. It is produced by 
Egyptian International Pharmaceutical Industry Company (EIPICO) 
with a commercial name CefotaxP®P. 
Animals 
Thirty adult male waster albino rats (150-180 g body weight) were 
obtained from the Animal House, Faculty of Veterinary Medicine, 
Cairo University, Egypt. They were maintained on the standard 
pellet diet and tap water ad libitum and were kept in plastic cages 
under a 12 hr light/dark cycle and room temperature 22-24 °C. Rats 
were acclimatized to the environment for two weeks prior to 
experimental use. The protocol for the albino rat study was 
approved by the Institutional Animal Care and Use Committee 
(IACUC) of Cairo University (108-2015).  
Experimental design 
Rats were randomly divided into three groups. Group 1: injected 
with 1 ml of distilled water and served as control; Group 2: IM 
injected with cefotaxime (90 mg/kg b. wt.) and Group 3: IM injected 
with cefotaxime (180 mg/kg b. wt.). Cefotaxime was injected by IM 
route twice daily at 12 h intervals for 7 consecutive days. Blood 
collection was performed 24 h after the end of the7Pth Pd by retro-
orbital sinus puncture from each anesthetized rats with ether. The 
collected blood samples were allowed to clot and serum samples 
were obtained by centrifugation at 3000 rpm for 10 min, the serum 
was separated immediately and stored at-20 °C until determination 
of biochemical parameters. 
Biochemical analysis 
Creatinine[9], urea[10], glucose, total protein[11], AST, ALT [12], 
albumin[9], total bilirubin [13]were determined in serum using kits 
from Diamond Diagnostic Company, Egypt. Sodium, potassium [14] 
International Journal of Pharmacy and Pharmaceutical Sciences 




Int J Pharm Pharm Sci, Vol 7, Issue 11, 312-315 
 
313 
and calcium [15] were determined using kits from Spin react 
Company, Spain. Cholesterol [16], Triglycerides [17], HDL-
cholesterol and LDL-cholesterol [18] were determined using kits 
from Vitro Scient Company, Egypt. All biochemical analysis was 
measured by using spectrophotometer. 
Histopathological studies 
Following complete necropsy of the experimental male rats, small 
fresh specimens from liver and kidney were collected and 
rapidlyfixedin 10 % formalin solution for at least 24 h. The specimens 
were processed through the conventional paraffin embedding 
technique (dehydration in ascending grades of ethylalcohol, clearing in 
different changes of xylene and embedding in different changes of 
melted paraffin wax at 60 °C). Paraffin blocks were cut by microtome 
into 5 microns. Thick sections which were stained with Haematoxylin 
and Eosin (H. E.) according to the method described in [19]. 
Statistical analysis 
The data were expressed as (mean±SE) and analyzed using SPSS 
(16) Software (SPSS Inc., Chicago, USA) and differences between the 
averages were examined by Duncan’s multiple range test. Mean 
values within a row with different superscript letters is significantly 
different (P ≤ 0.05). 
RESULTS 
Serum biochemical parameters 
The present study was designed to evaluate the effect of 
cefotaxime on the liver and kidney functions. Cefotaxime 
administration at two doses (90 and 180 mg/kg b. wt.) led to 
significant P≤0.05  increase in serum liver function marker 
enzymes (AST and ALT), total cholesterol, total bilirubin, 
triglyceride as compared with the control group. Renal products 
(urea and creatinine), sodium, potassium, calcium ions was 
significantly increased and the total serum protein showed a 
significant decrease as compared with the control group with the 
marked decrease of serum glucose level (table 1 and 2). 
Histopathological study 
Histopathological effects of cefotaxime on liver and kidneys were 
shown in fig. 1. The liver of the tested groups showed disturbed 
architecture with vacuolar degeneration of the hepatocytes. Main 
inflammatory cells were lymphocyte and plasma cells with expanded 
portal area and peri-vascular heamorrhages. The kidney of the 
tested groups showed inter-tubular hemorrhage with necrotic 
cellular debris in lumen of some renal tubules and intracellular 
inflammatory cellular infiltration, mainly mononuclear cells. 
 
Table 1: Serum AST, ALT, bilirubin, albumin, cholesterol, triglycerides, HDL-cholesterol and LDL-cholesterol levels in rats 7 d after 
treatment with cefotaxime (90 and180 mg/kg b. wt. Twice daily) as compared to control group 
Parameters Control Group 1 
Cefotaxime (90 mg/kg b. wt. twice daily) 
Group 2 







































































Note: Data are expressed as mean±SE, Values with different letters in the same row are significantly different at P≤0.05 (ANOVA with Duncan's 
multiple range test). 
 
Table 2: Serum creatinine, urea, sodium, potassium, calcium, glucose and total protein levels in rats 7 d after treatment with cefotaxime 
(90 and 180 mg/kg b. wt. Twice daily) as compared to control group 
Parameters Control Group 1 
Cefotaxime (90 mg/kg b. wt. twice daily) 
Group 2 






























































Note: Data are expressed as mean±SE, Values with different letters in the same row are significantly different at P≤0.05 (ANOVA with Duncan's 
multiple range test). 
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Fig. 1: Photomicrographs of Hematoxylin–Eosin staining of 
hepatic and renal sections of control and experimental rats. 
Hepatic and renal tissue sections were showen at 200× 
magnification 
 
A) Liver of rat injected with distilled water showing normal 
hepatic structure. 
B) Kidney of rat injected with distilled water showing normal 
renal structure. 
C) Liver of rat injected with cefotaxime (90 mg/kg b. wt. Twice 
daily for 7 d) showing peri-vascular hemorrhage and peri-ductal 
inflammatory cells. 
D) Kidney of rat injected with cefotaxime (90 mg/kg b. wt. Twice 
daily for 7 d) showing intracellular inflammatory cellular infiltration, 
mainly mononuclear cells. 
E) Liver of rat injected with cefotaxime (180 mg/kg b. wt. twice 
daily for 7 d) showing congestion of portal blood vessels with fibrin 
emboli. 
F) Kidney of rat injected with cefotaxime (180 mg/kg b. wt. twice 
daily for 7 d) showing inter-tubular hemorrhage with necrotic 
cellular debris in lumen of some renal tubules. 
DISCUSSION 
The biochemical indices evaluated in this study are useful 
parameters to indicate impairment in functional capacities of the 
organs. Cefotaxime produced significant increase in both liver 
enzymes (AST and ALT) concentrations in the serum of treated 
groups than those recorded in the control group. Similar results 
were observed by [20] who found that, ceftriaxone therapy 
associated with elevated liver enzymes in rats. On the other hand, 
these results were inconsistent with those obtained after SC 
injection of cefazolin to male rats, which lead to significantly 
decreased alanine aminotransferase and aspartate aminotransferase 
activities in the serum of treated rats [21]. Cefotaxime produced 
asignificant increase in total bilirubin and asignificant decrease in 
albumin concentrations in the serum of treated groups. The 
obtained results were similar to those obtained by [22] who 
suggested that ceftriaxone which displaced bilirubin from albumin 
and increased erythrocyte-bound bilirubin and unbound bilirubin 
should be used with caution in high-risk jaundiced newborns. 
Cefotaxime produced significant elevation in total cholesterol, 
triglycerides, low density lipoprotein-cholesterol and significant 
decrease in high density lipoprotein-cholesterol concentrations in 
serum of treated groups than recorded in the control group. Similar 
results were obtained by [20] after IM injection of ceftriaxone to 
rats. These obtained biochemical changes might be attributed to 
damage to hepatocytes. The histopathological finding in the liver of 
cefotaxime treated rats obtained in this study was consistent with 
those recorded following cefdinir administration which produces a 
mixed inflammatory infiltrate in the portal area with neutrophils, 
plasma cells, lymphocytes and occasional eosinophils. Moreover, 
liver biopsy demonstrated mixed inflammatory infiltrate in the 
lobule with mild central venulitis and moderate hepatocellular and 
canalicularcholestasis [23]. Toxic hepatitis associated with 
ceftriaxone had been also recorded [24]. 
The functional capacity of the kidney can be measured by blood 
concentrations of excretory and electrolyte constituents. 
Furthermore, renal function tests are required either to demonstrate 
the presence or absence of an active lesion in the kidney or to assess 
the normal functioning capacity of different parts of the functioning 
unit, nephron [25]. Cefotaxime in doses of 90 and 180 mg/kg b. wt. 
twice daily for 7 d caused asignificant increase in creatinine and 
urea concentrations in the serum of treated rats. This result was 
consistent with those reported by [26] who found that treatment of 
male Sprague-Dawley rats with intravenous cephaloridine (1.2 g/kg) 
for 24 h markedly increased plasma creatinine and blood urea 
nitrogen levels. Moreover, ceftriaxone produced an increase in 
serum creatinine and urea levels of treated rats [27]. This result was 
inconsistent with those reported after the administration of 
cefpiromesulphate and cefazoline sodium in rabbits [28]. Sodium, 
potassium and calcium levels in serum were significantly increased; 
this elevation might be attributed to the diuretic effect of cefotaxime, 
decrease of the glomerular filtration and decrease of tubular 
reabsorption of these electrolytes in the renal tubules. 
Hypernatremia could in a way serve as an indicator of liver disease 
[29]. Hyperkalemia is a more dangerous condition because of its 
effect on the heart, but it rarely occurs unless renal function is 
depressed. The significant increase in serum Ca2+
1. Ings RM, Fillastre JP, Godin M, Leroy A, Humbert G. The 
pharmacokinetics of cefotaxime and its metabolites in subjects 
with normal and impaired renal function. Rev Infect Dis 1982;4 
Suppl:379-91. 
may be due to cell 
membrane damage as a result of exposure to drugs or inhibition of 
uptake by cells and tissues [30].  
The obtained results were consistent with those obtained after 
administration of cefoperazone to rats [31]. Moreover, cefamandole 
induced hypercalcemia in rats [32]. Cefotaxime administration caused 
highly significant decrease in serum glucose, this result was similar 
with those reported by [33] who observed that, cefminox caused a 
slight decrease in serum glucose in male rats, administration of 
cefpiromesulphate and cefazoline sodium in rabbits [28] and after IM 
injection of cefamandole in rats [32]. Cefotaxime caused adecrease in 
serum protein level; this was consistent with that recorded in rabbits 
following administration of both cefpiromesulphate and cefazoline 
sodium [28] and after oral dosing of cefmtaline [34]. These obtained 
biochemical changes might be attributed to damage of the renal 
tubules cells. The histopathological findings in kidneys of cefotaxime 
treated rats obtained in this study were consistent with those obtained 
by [35] who observed that, cephaloridine administration to rats 
produced degeneration and/or necrosis of the renal proximal tubular 
epithelia. Cefodizime caused renal proximal tubular changes such as 
necrosis, hyaline cast and calcification, suggesting renal disorders [36]. 
CONCLUSION 
It could be concluded that IM administration of cefotaxime caused a 
significant alterations in some biochemical parameters as serum 
(AST, ALT, total bilirubin, Cholesterol, Triglycerides, LDL-
cholesterol, albumin and HDL-cholesterol concentrations). 
Cefotaxime caused hepatic and renal histopathological alterations. 
Cefotaxime is not a drug of choice and not preferable to animals or 
patients that suffering from hepatic and renal disorders. 
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